摘要
目的探讨莫沙比利联合帕罗西汀治疗肠易激综合征的临床疗效和安全性。方法运用随机数字表法将88例肠易激综合征患者均分为A组和B组,A组仅给予莫沙比利治疗,B组加用帕罗西汀治疗,治疗8周后,比较两组患者的临床疗效和不良反应发生情况。结果B组患者治疗总有效率为95.45%,明显高于A组的81.82%(P<0.05);B组患者不良反应发生率无明显增加,与A组比较差异无统计学意义(P>0.05)。结论莫沙比利联合帕罗西汀治疗肠易激综合征疗效确切,安全可靠,不良反应少。
Objective To investigate the clinical efficacy and safety of paroxetine combined with mosapride in treating irritable bowel syndrome. Methods 88 patients with irritable bowel syndrome were collected and divided into the group A and B by using the random number table. The group A was only given mosapride, while the group B was given paroxetine plus mosapride. Then the clinical efficacy and the occurrence situation of adverse reactions after 8- week treatment were compared between the two groups. Results After 8- week treatment, the total effective rate was 95.45% in the group B, which was significantly higher than 81.82% in the group A, the difference of the total effective rates between the two groups had statistical significance（ P 〈 0.05）. The adverse reaction rate in the group B had no obvious increase, the difference between the two groups had no statistical significance（ P 〉 0. 05）. Conclusion Paroxe- fine combined with mosapride for treating irritable bowel syndrome has definite effect, and is safe and reliable with less adverse re- actions.
出处
《中国药业》
CAS
2013年第17期70-71,共2页
China Pharmaceuticals
基金
国家自然科学基金
项目编号:81170340
